申请人:GLAXOSMITHKLINE IP NO 2 LTD
公开号:WO2013067302A1
公开(公告)日:2013-05-10
The present invention relates to a method of treating T cell mediated inflammatory immune diseases or T cell mediated hypersensitivity diseases, which comprises administering to a human in need thereof an effective amount of a compound which inhibits EZH2 and/or EZH1, or a pharmaceutically acceptable salt thereof.